News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Small cell lung cancer – a disease for which no new drugs have been approved for many years – has shown itself vulnerable to an agent that disables part of tumor cells’ basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

Tags: Genomics, LungCancer

  • Findings by Dana-Farber scientists and others show the disarray in the on-off mechanism – known as methylation – is one of the defining characteristics of cancer and helps tumors adapt to changing circumstances.

Tags: BasicResearch, Genomics

  • Researchers report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand.

Tags: chemotherapy, StemCellTransplant

  • Dana-Farber and colleagues report that an oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) in a phase 2 clinical trial.

Tags: Leukemia

  • Dana-Farber researchers report that multiple myeloma is driven to spread by a subset of the myeloma cells within a patient’s body, and that attacking those specific subsets with targeted drugs may be better targets for therapy.

Tags: BasicResearch, MultipleMyeloma

  • Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission.

Tags: Lymphoma, Immunotherapy

  • The "molecular mail" sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study by researchers at Dana-Farber Cancer.

Tags: BasicResearch, MultipleMyeloma

  • The Leapfrog Group has named Dana-Farber Cancer Institute to its annual list of Top Hospitals for the first time.

Tags: Honors, PatientSafety

  • Fifty-seven physicians and surgeons affiliated with Dana-Farber have been named to Boston magazine's annual "Top Doctors" guide.

Tags: Honors

  • Scientists analyzed tissue samples from patients who had — and had not — responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.

Tags: Melanoma, Immunotherapy

Showing 11-20 of 563 items